Literature DB >> 11786476

Urotensin II evokes potent vasoconstriction in humans in vivo.

Felix Böhm1, John Pernow.   

Abstract

The peptide urotensin II (U II) evokes potent vasoconstriction in non-human primates. In human blood vessels studied in vitro variable effects of U II are reported; vasoconstriction, vasodilatation or no response. It is therefore of importance to determine the vascular effect of U II in humans in vivo. U II (0.1 - 300 pmol min(-1)) was infused into the brachial artery of nine healthy volunteers. Changes in forearm blood flow (FBF) were determined by venous occlusion plethysmography. U II induced dose-dependent reduction in FBF. A threshold response was obtained by 1 pmol min(-1), and the highest dose of U II (300 pmol min(-1)) reduced FBF by 31+/-4% (P<0.01). FBF returned to baseline values within 30 min. This study demonstrates that U II produces potent vasoconstriction in humans in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786476      PMCID: PMC1573112          DOI: 10.1038/sj.bjp.0704448

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.

Authors:  Y Coulouarn; I Lihrmann; S Jegou; Y Anouar; H Tostivint; J C Beauvillain; J M Conlon; H A Bern; H Vaudry
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

2.  Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

Authors:  A Stirrat; M Gallagher; S A Douglas; E H Ohlstein; C Berry; A Kirk; M Richardson; M R MacLean
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-02       Impact factor: 4.733

3.  Effects of urotensin II in human arteries and veins of varying caliber.

Authors:  C Hillier; C Berry; M C Petrie; P J O'Dwyer; C Hamilton; A Brown; J McMurray
Journal:  Circulation       Date:  2001-03-13       Impact factor: 29.690

4.  Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; A P Davenport; T Bennett
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Authors:  R S Ames; H M Sarau; J K Chambers; R N Willette; N V Aiyar; A M Romanic; C S Louden; J J Foley; C F Sauermelch; R W Coatney; Z Ao; J Disa; S D Holmes; J M Stadel; J D Martin; W S Liu; G I Glover; S Wilson; D E McNulty; C E Ellis; N A Elshourbagy; U Shabon; J J Trill; D W Hay; E H Ohlstein; D J Bergsma; S A Douglas
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

6.  Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries.

Authors:  F E Bottrill; S A Douglas; C R Hiley; R White
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

7.  Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

8.  Potent vasoconstrictor effects and clearance of endothelin in the human forearm.

Authors:  J Pernow; A Hemsén; J M Lundberg; J Nowak; L Kaijser
Journal:  Acta Physiol Scand       Date:  1991-03

9.  Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes.

Authors:  D Pearson; J E Shively; B R Clark; I I Geschwind; M Barkley; R S Nishioka; H A Bern
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

  9 in total
  28 in total

Review 1.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

2.  Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling.

Authors:  Ana Patrícia Fontes-Sousa; Carmen Brás-Silva; Ana Luísa Pires; Daniela Monteiro-Sousa; Adelino F Leite-Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-14       Impact factor: 3.000

3.  Endothelial progenitor cells & translational research.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

4.  Renal impairment, hypertension and plasma urotensin II.

Authors:  Ari Mosenkis; Radhakrishna R Kallem; Theodore M Danoff; Nambi Aiyar; Jonathan Bazeley; Raymond R Townsend
Journal:  Nephrol Dial Transplant       Date:  2010-07-09       Impact factor: 5.992

Review 5.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

6.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).

Authors:  Valeria Camarda; Martina Spagnol; Wei Song; Raffaella Vergura; Adelheid L Roth; Jonathan P Thompson; David J Rowbotham; Remo Guerrini; Erika Marzola; Severo Salvadori; Paolo Cavanni; Domenico Regoli; Stephen A Douglas; David G Lambert; Girolamo Calò
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

7.  A new ligand for the urotensin II receptor.

Authors:  Valeria Camarda; Remo Guerrini; Evi Kostenis; Anna Rizzi; Girolamo Calò; Almut Hattenberger; Marina Zucchini; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects.

Authors:  Z Wenyi; S Suzuki; M Hirai; Y Hinokio; Y Tanizawa; A Matsutani; J Satoh; Y Oka
Journal:  Diabetologia       Date:  2003-06-27       Impact factor: 10.122

9.  Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response.

Authors:  Sheila M Gardiner; Julie E March; Philip A Kemp; Terence Bennett
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

10.  Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.

Authors:  R T Bennett; R D Jones; A H Morice; C F C Smith; M E Cowen
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.